Xie, Y et al Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation BMJ Medicine, March 18, 2026
[DOI] [PubMed] [Google Scholar] 125.Saxena A.R., Banerjee A., Corbin K.D., Parsons S.A., Smith S.R
This approach suits individuals new to GLP-1 therapy, those with complex medical histories, or patients who value frequent dose adjustment guidance without coordinating separate pharmacy and clinical relationships
Who is Integrative Peptides Understanding a supplement company requires looking beyond their marketing
Body weight determines your target cumulative dose, with heavier patients needing more medication over time